Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Bayer Obtains Approval for Eylea for Macular Edema Secondary to Retinal Vein Occlusion
June 30, 2015
- Study for Myelodysplastic Syndrome in Japan: SymBio
June 30, 2015
- Takeda Chairman Hasegawa Gives Up Representative Rights
June 29, 2015
- Aspen Japan Takes Over Decadron from MSD
June 29, 2015
- UCB Japan Applies for Approval of Antiepileptic Agent Lacosamide in Japan
June 29, 2015
- RaQualia Regains Domestic Rights to Dalbavancin from Allergan
June 29, 2015
- Lixiana Gets EU Regulatory Approval: Daiichi Sankyo
June 26, 2015
- EU OKs Fycompa as Adjunct Therapy for PGTC Seizures: Eisai
June 26, 2015
- Sosei Group “Not in Hurry” to License Out Compounds Obtained through Heptares Acquisition: President Tamura
June 26, 2015
- Naldemedine Meets Primary, Secondary Endpoints in Japanese PIII Study for the Treatment of OIC in Cancer Patients: Shionogi
June 26, 2015
- Novartis Seeks Japan Approval of Ceritinib
June 25, 2015
- Takeda CFO Roger to Resign in under 2 Years
June 25, 2015
- Japan Vaccine Studying Marketing Strategy for 3 Seasonal Flu Vaccines, Marketing System for Adult Vaccines as Well
June 24, 2015
- AnGes MG Grants MTPC Marketing Rights for HGF Gene Treatment for Peripheral Vascular Diseases in Japan
June 24, 2015
- Hemophilia A Treatment Candidate to Move to PIII During 2015 Based on Favorable Results in PI/II Studies: Chugai
June 24, 2015
- Lilly Japan Oncology Chief Hopeful on Cyramza Growth
June 23, 2015
- Favorable PIII Data Out for Nichi-Iko’s Remicade Biosimilar
June 23, 2015
- Biogen Idec Japan Rebranded as Biogen Japan
June 23, 2015
- Opdivo Wins European Approval for Advanced Malignant Melanoma: BMS
June 23, 2015
- Fycompa Approved as Adjunctive Treatment for Primary Generalized Tonic-Clonic Seizures in US: Eisai
June 23, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…